Behzad Noorian, MD
Infectious Disease · Torrance, CANPI 1467536128
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $116,121 of the $119,889 with a category attached, or 96.9%. AbbVie accounts for 97.8% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2021 at $76,334 and has fallen 99.7% since, to $238 in 2025. Among infectious disease clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 187 payments — averaging $641.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$117K
- Shionogi Inc$682
- Melinta Therapeutics, LLC$430
- Viiv Healthcare Company$397
- Merck$355
- AstraZeneca$250
- plus $525 from 7 others
What the payments were for
- Consulting fees$200%
- Speaking & faculty fees$116,12197%
- Food & beverage$3,7243%
- Education$230%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 85 | $117,249 |
| Shionogi Inc | 37 | $682 |
| Melinta Therapeutics, LLC | 6 | $430 |
| Viiv Healthcare Company | 24 | $397 |
| Merck | 22 | $355 |
| AstraZeneca | 2 | $250 |
| Amarin Pharma, Inc. | 1 | $138 |
| Avanir Pharmaceuticals, Inc. | 1 | $125 |
| Merz North America, Inc. | 1 | $95 |
| Gilead | 3 | $69 |
| Galderma Laboratories, L.p. | 2 | $40 |
| Revance Therapeutics, Inc. | 2 | $37 |
| Bayer | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$119,889 in reported general payments places this provider in the 95th percentile of 856 infectious disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ulticare Pen NeedlePen Needle, Diabetic | 12 | $653 |
| Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide | 13 | $518 |
| Atorvastatin Calcium | 24 | $307 |
| Pravastatin Sodium | 26 | $304 |
| Metformin Hcl | 34 | $248 |
| Losartan Potassium | 12 | $191 |
| Levothyroxine Sodium | 15 | $165 |
| Lisinopril | 28 | $162 |
| Tamsulosin Hcl | 23 | $136 |
| Gabapentin | 11 | $125 |
| Amlodipine Besylate | 29 | $102 |
| Carvedilol | 17 | $74 |
| Atenolol | 12 | $51 |
| Alprazolam | 17 | $50 |
| Chlorthalidone | 13 | $44 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Torrance
- James McKinnellTorrance$762K
- Eric DaarTorrance$72K
- Claire PomeroySacramento$2.6M
- Javeed SiddiquiRoseville$1.5M
- George SakoulasSan Diego$902K
- Arthur JengSylmar$766K
- Jay GladsteinLos Angeles$657K
- Tulika SinghOrange$654K
- Otto YangLos Angeles$472K
- Franco FelizartaBakersfield$440K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.